FDA Says Interchangeable Biosimilars Are Coming
Although the United States still does not have a single interchangeable biosimilar approved, the FDA expects there to be one within the next 2 years, reported RAPS. The FDA is currently reviewing comments on draft guidance on biosimilar interchangeability and still has to issue either revised draft guidance or final guidance in the next 2 years. Currently, 9 companies have 14 biosimilar applications submitted with the agency.
Rural Counties in Nevada Lack Marketplace Insurers
In 2018, nearly all of Nevada’s rural counties will not have a single health insurer on the individual marketplace. Overall, 8000 people will lose insurance and have no other options, reported the Reno Gazette-Journal. Nevada Governor Brian Sandoval said his administration is working to ensure there is at least a safety net in place. He has vocally opposed the Senate healthcare bill, which would roll back Medicaid expansion, and he and the state’s Republican senator, Dean Heller, have not changed their minds on the issue.
Allergists Warn of Shortages for Insect Stings
This summer in the United States, allergy shots that prevent life-threatening reactions to insect stings are in short supply. Extracts for the shots have been scarce, plus a contamination issue caused one manufacturer to shut down production, reported Kaiser Health News. As a result, allergists are rationing their supplies and only giving them to patients who need the doses the most.
FIT Completion, Yield Rates in CRC Screening Similar After New Screening Guidelines
October 22nd 2024Patients were found to have similar completion and yield rates for the fecal immunochemical test (FIT) at both 45 years and 50 years, making screening for colorectal cancer (CRC) effective in younger patients.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
October 21st 2024Examining care transitions in hospitalized patients revealed lower diagnostic error rates compared with traditional methods, highlighting the effectiveness of this approach in identifying diagnostic challenges.
Read More
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More